We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Merck KGAA | TG:MRK | Tradegate | Ordinary Share |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 2.25 | 1.49% | 152.90 | 151.60 | 152.85 | 154.50 | 150.15 | 150.95 | 5,918 | 18:32:49 |
From May 2019 to May 2024
By Mauro Orru
Merck KGaA (MRK.XE) will invest 250 million euros ($275.5 million) to deliver a new facility in Switzerland for biotech development and manufacturing for clinical studies, the company said Monday.
The Germany pharmaceuticals and chemicals company said construction of the new facility in Corsier-sur-Vevey is expected to be completed in 2021 and enter service by the end of 2022.
"Our investment in this biotech-development facility in Switzerland is strongly related to the growth and progression of our health-care pipeline, and our confidence in its future potential," said Belen Garijo, member of the Merck executive board and CEO for health care.
Merck added that the new facility would consist of a building with 15,700 square meters of development space.
The facility will house roughly 250 employees.
Write to Mauro Orru at mauro.orru@wsj.com; @MauroOrru94
(END) Dow Jones Newswires
January 27, 2020 09:03 ET (14:03 GMT)
Copyright (c) 2020 Dow Jones & Company, Inc.
1 Year Merck KGAA Chart |
1 Month Merck KGAA Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
